Malignancies occur with a higher incidence rate and manifest earlier in life in patients with
primary immunodeficiency disorders (PIDs) than in the general population. However, no
universal mechanism of malignancy predisposition in patients with PIDs has been
determined. Despite strong support for the physiologic role of tumor immunosurveillance
and the increasing success of strategies in immunologic tumor therapy, which include
checkpoint inhibition, mAbs, and engineered T-cell antigen receptors, the incidence and …